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ABSTRACT
The need for new drugs to treat microbial infections is pressing. The great progress made in the middle part of the twentieth
Century was followed by a period of relative inactivity as the medical needs relating to infectious disease in the wealthier
nations receded. Growing realisation that anti-infectives are needed inmany parts of the world, to treat neglected diseases as
well as to combat the burgeoning risk of resistance to existing drugs, has galvanised a new wave of research into anti-
microbial drugs. The transfer of knowledge from the Pharmaceutical industry relating to the importance of understanding
how to target drugs successfully within the body, and improved understanding of how pathogens interact with their hosts, is
driving a series of new paradigms in anti-infective drug design. Here we provide an overview of those processes as an
introduction to a series of articles from experts in this area that emerged from a meeting entitled “Emerging Paradigms in
Anti-Infective Drug Design” held in London on the 17th and 18th September 2012. The symposium was organised jointly
by British Society for Parasitology (BSP) and the Biological & Medicinal Chemistry sector of the Royal Society of
Chemistry (RSC) and held at the London School of Hygiene & Tropical Medicine. The symposium set out to cover all
aspects of the identiﬁcation of new therapeutic modalities for the treatment of neglected and tropical diseases. We aimed to
bring together leading scientists from all the disciplines working in this ﬁeld and cover the pharmacology, medicinal
chemistry and drug delivery of potential new medicines. Sessions were held on: “Target diseases and targets for drugs”,
“Target based medicinal chemistry”, “Bioavailability and chemistry”, “Targeting intracellular microbes”, “Alternative
approaches and models”, and “New anti-infectives – how do we get there?”
This symposium was organised by Simon Croft (LSHTM) and Mike Barrett (University of Glasgow) for the BSP, and
David Alker (David Alker Associates) and Andrew Stachulski (University of Liverpool) for the Biological & Medicinal
Chemistry sector of the RSC.
Key words: Anti-infectives, drug design, antimicrobials, pharmacokinetics.
INTRODUCTION
Microbial pathogens remain responsible for around
one quarter of all human deaths (Wang et al. 2012)
with an overwhelming majority of these in the less
well developed nations. Finding drugs to kill
pathogens should be relatively easy given that they
are genetically distinct from humans with a plethora
of potentially selective drug targets. However, in
many instances, the identiﬁcation of ‘druggable’
targets alone has not been suﬃcient to underpin
new drug development. Diﬃculties in reaching
targets can relate to many issues including diﬀerential
expression during complex life-cycles and, crucially,
interactions between host and pathogen that
inﬂuence exposure. Drugs have been used to cure
microbial infections for centuries with natural pro-
ducts being predominant. These include quinine, a
product of the Peruvian Cinchona tree, used to treat
fevers for well over four hundred years and the
antimicrobial metabolites produced by fungi and
soil-dwelling bacteria which, from penicillin to
ivermection, transformed health in the 20th century
(Greenwood, 2008). It was also the search for new
antimalarials that spawned ‘rational chemotherapy’
from the use of methylene blue (Guttman and
Ehrlich, 1891). The chemical derivation of mepa-
crine, chloroquine and other pharmaceuticals oﬀer
key early examples of medicinal chemistry establish-
ing structure-activity relationships to optimize drugs
(Greenwood, 1995).
Progress in antimicrobial therapy reached its
zenith in the period from 1950 to 1980 when a
plethora of new families of antibiotics were found to
target diﬀerent proteins, nucleic acids and membrane
components (Greenwood, 2008). The ﬁnal years of
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the twentieth century, however, witnessed a dramatic
decrease in discovery and development of anti-
infective drugs, partly due to the fact that the ‘low
hanging fruit’ had already been picked, partly due to
a perception that adequate coverage was now pro-
vided for antimicrobial chemotherapy and partly
due to the relatively low returns on investment on
anti-infectives compared with drugs aimed at chronic
diseases in aﬄuent nations (Piddock, 2012). The
reductionist claims of molecular biology led to quests
for compounds to inhibit proteins that, with the
beneﬁt of hindsight, had little prospect of moving
towards drugs. In the past few years, a number of
key innovations have started to reverse this process.
At the economic level, a realization that proﬁts from
antimicrobials, particularly those aimed at diseases
of the developing world, were insuﬃcient to meet the
costs in development, stimulated the establishment of
a series of product development partnerships (PDPs)
aiming to bring compounds forward (Croft, 2005;
Nathan, 2012). The appearance of these organiz-
ations, over a period when large pharmaceutical
companies was ﬁnding it increasingly diﬃcult to
license small molecules for any disease, has also led to
industrial re-engagement with pathogen-based dis-
ease (Gamo et al. 2010; Witty, 2011). The emergence
of a previously unthinkable willingness to release
intellectual property on compounds that cure diseases
like malaria, tuberculosis and the neglected tropical
diseases has been a revelation. At the same time, the
experiences from the pharmaceutical industry on
the centrality of pharmacology to the drug develop-
ment process led to a new realism in the choice of
chemotypes that are suitable for further development
as antimicrobial agents. As a consequence, the last
ﬁve years have seen the appearance of pipelines of
compounds entering clinical trials to treat several of
the diseases associated with poverty (www.mmv.org;
www.tballinance.org; www.dndi.org). It is critical
that this momentum is sustained if we are to defeat
some of mankind’s most persistent scourges and to
expand this vision to include novel antibacterials in
an era where drug resistance is threatening human
and animal health.
In spite of our knowledge of the aetiological agents
of most infectious diseases, humankind has been
woefully inept at their control, let alone eradication.
To date, the only human infectiousmicrobial agent to
have been eradicated is the small pox virus targeted
by an intensive vaccination campaign. Currently
optimism exists that two more microbes might be
in line for eradication. The polio virus, also targeted
by a vaccination campaign (Minor, 2012) and Guinea
worm (Centers for Disease Control and Prevention,
2012), whose demise is being brought about through
a public health-based campaign of ﬁltering drinking
water that carries the Cyclops arthropods that trans-
mit the worm larvae have declined substantially in
incidence. In the meantime novel human-infectious
agents are emerging. For example, recent inﬂuenza
(Watanabe et al. 2012) and Corona virus (Weinstein,
2004) outbreaks have caused alarm worldwide. Also
of concern has been the rapid emergence and spread
of resistance to existing antimicrobial drugs from
hospitals. The ability of resistance genes to spread in
microbial communities has demonstrated how
dangerous the indiscriminate use of antibiotics in
domestic livestock can be (Garcia-Alvarez, 2012).
Tuberculosis bacteria resistant to most of the current
drugs now exist (Haydel, 2010). In malaria, most of
the drugs used 20 years ago are useless due to wide
spread resistance. Even use of the artemisinin
derivatives is threatened by emerging resistance
(White, 2012). The requirement for a robust and
sustained pipeline of anti-microbial drugs is impera-
tive if we are to control microbial infections in the
developedworld and turn the tide on themultitude of
infectious agents that continue to thwart society in
the developing world.
ANTI-PATHOGEN AND ANTI-TARGET-BASED
SCREENS, SUCCESSES AND DISAPPOINTMENTS
During the 1980s it became relatively easy to identify
genes that encode proteins and to produce those
proteins in quantities suﬃcient to enable screening
of series of chemical compounds for inhibitory
activity. This process accelerated with the advent
of whole genome sequencing in the late 1990s and
the expansion of those technologies into the 2000s
driven by the completion of genome sequences
for Mycobacterium tuberculosis (Cole et al. 1998),
Plasmodium falciparum (Wirth, 2002) andLeishmania
and Trypanosoma species (El-Sayed et al. 2005).
It was often quoted that all potential drug targets
were now in reach, and miniaturized and robotic
systemsmade the screening ofmillions of compounds
feasible.
The scientiﬁc literature of the 1990s into the 2000s
is replete with descriptions of proteins whose activity
could be inhibited by a range of molecules, few of
which had the physicochemical properties compati-
ble with potential for use as drugs. Molecular
structures of proteins made it possible to predict
which chemical ligands could bind within active sites
and a multitude of studies were performed to ﬁnd
such molecules and use them as leads to generate
more compounds. In the trypanosomatids, enzymes
involved in the metabolism of the unusual thiol
compound, named trypanothione (Fairlamb et al.
1985), were seen as particularly useful drug targets
given their exclusive presence in these protozoa and
absence in man. However, in spite of a multitude of
screening and structure-based eﬀorts to identify
selective inhibitors this system, like many others,
failed to yield credible compounds for development
as drugs (Gilbert, 2013). The development of genetic
methods that enabled testing of enzyme essentiality
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appeared to oﬀer a short cut to ensure the value of
particular targets. A seminal paper from investigators
at GSK in 2007, however, reported that the
systematic expression of scores of target proteins
and their screening against libraries of hundreds of
thousands of compounds yielded absolutely nothing
in terms of new antimicrobials (Payne et al. 2007).
Other companies had been suﬀering similarly frus-
trating times and the academic laboratories involved
in rather lower-level throughput screening could
report the same. Target-based screening has to date
failed to deliver its full potential with a few notable
exceptions including new inhibitors of dihydrofolate
reductases, DNA topoisomerases and C14-α-sterol
demethylases in fungi. Notwithstanding, today
within the MMV portfolio there are compounds
whose activity was aimed at speciﬁc targets including
dihydroorotate dehydrogenase (Booker et al. 2010).
The electron transport chain, essential inPlasmodium
pyrimidine biosynthesis, has also been targeted with
potent quinolone-based compounds (Stocks et al.
2013). Developing more sophisticated modelling
methods continues to contribute towards lead com-
pound identiﬁcation and reﬁnement against speciﬁc
targets but also increasing the use of physicochemical
constraints to enhance the probability of compounds
emerging with drug-like features (Cunningham et al.
2013). In the trypanosomatids, protein farnesyl
transferase and N-myristoyl transferase were shown
to be targets against which very potent compounds
could be designed (Frearson et al. 2010). However,
in these latter cases too there has been a diﬃculty in
adapting compounds that are excellent inhibitors
of the enzymes and potent killers of the pathogens
to drugs (Tate et al. 2013). These diﬃculties relate to
the problems surrounding pharmacokinetics and
pathogen tropisms within hosts, but optimism
remains that as our knowledge of drug interactions
within the mammalian system increases, so potent
inhibitors can be adapted to allow them to reach their
targets.
Many of the compounds developed as antimicro-
bials emerged well before the advent of molecular
targets for drugs and even before the luxury of
eﬀective in vitro cultivation methods. The com-
pounds were found by screening of chemicals against
pathogens within animal models, for example around
300000 compounds were screened as potential anti-
malarials in the 1970s (Ockenhouse et al. 2005).Those
screening programmes, by necessity in the absence of
the reductionist approaches that came later, took the
entire systeminto account.That is to say the chemicals
they used needed to inhibit targets within pathogens,
themselves distributed to infected tissues within the
host. Hence any compounds which did not possess
pharmacological properties compatible with suitable
stability and distribution within the host would never
be selected. Today we are reverting towards such a
‘systems pharmacology’ (Iyengar, 2012) taking into
account all of the parameters required to produce a
suitable drug. As available compound numbers have
increased, large-scale in vivo screening is not viable,
hence it is usually necessary to determine PK
properties of drugs independently of potency and
then to marry datasets prior to choosing those which
are selected for in vivo screening.
There is now a general acceptance that the best
antimicrobial agents have emerged by screening
compound libraries against whole organisms in vitro
and then taking hits to optimize for their in vivo
pharmacology. Thus the antimalarial pipeline cur-
rently contains over a dozen compounds, most of
which came through screening against the whole
organism rather than by aiming at a particular target.
For tuberculosis, the kinetoplastid protozoa and
many bacteria, the same is true. A challenge then
is to identify targets within the parasites that are
functional in the mammalian stages of the life-cycle.
The selection of resistant strains can help to identify
the target with whole genome sequencing pointing
to mutations that lead to resistance (provided the
mutations are within the target rather than aﬀecting
other aspects of drug-pathogen interaction such as
entry into or eﬄux from cells). The use of high-
throughput RNAi screens in trypanosomes has
proven hugely successful in identifying loss of
function mutations that can allow parasites to grow
in the presence of drugs and thus point to potential
modes of action (Horn, 2013). Another route has
been tomeasure themetabolome of pathogens treated
with compounds in attempts to identify whether
enzyme products and substrates change in ways
pointing to selective inhibition (Creek and Barrett,
2013). The phenotypic whole-organism screens also
pick out compounds that may act against multiple
targets, and ‘polypharmacology’ where multiple
targets are hit by a single drug certainly contributes
to the superiority of the phenotypic screening route;
clearly exampled in kinases (Knight et al. 2010).
However, many compounds that are highly potent
in phenotypic screens still fail as drugs as the other
part of the ‘system’ (i.e. interactions within the host’s
biochemical environment) must also be surmounted.
It is the appreciation of these pharmacological criteria
that is now guiding the development of improved
antimicrobial agents. Expression of target genes in
highly tractable organisms like yeast oﬀers another
route to seek inhibitors of enzymes that function
within a cellular context, and has been successfully
used to identify new inhibitors of inositol phosphor-
ylceramide synthase from Leishmania (Norcliﬀe
et al. 2013).
THE GROWTH OF PK, PD AND ADME-TOX-BASED
APPROACHES
It is critical to optimize pharmacological features to
ensure that drugs are not toxic to host animals at
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doses required to kill pathogens. Moreover, com-
pounds must be distributed to the tissues in which
their target pathogens have localized and they must
be stable enough and remain available in suﬃcient
quantities to exert their anti-pathogen eﬀect. Several
examples exist whereby compound selection was
driven primarily through optimization of PK/PD
parameters. For example, the benzoxaborole class
of compounds were shown to have some activity
against Trypanosoma brucei in vitro (albeit of rela-
tively low potency) – but in vivo they were shown to
be eﬃcacious against the T. brucei acute mouse
model (Jacobs et al. 2011). Since the standard
model for Stage 2 HAT involves a six month
follow-up post-treatment to seek parasites in
blood, SCYNEXIS pursued a lead optimization
programme to determine levels of compound in
brain and compared these to drug doses needed to kill
and the time of exposure required. SCYX-7158,
which emerged from this work is now in phase 1
clinical trials (Wring et al. 2013).
For Plasmodium, MMV has implemented a very
rigorous series of protocols to enable PK and PD
proﬁling of compounds, with plasma half-life,
protein binding and volume of distribution, as well
as the PD property of rate of kill (Anthony et al.
2012) seen as key criteria to advance compounds.
Only compounds that combine satisfactory PK/PD
relationships are now considered within the MMV
target product proﬁle (TPP) of single-dose drugs for
radical cure (Jimanez-Diaz et al. 2013). For leishma-
niasis and tuberculosis it has proven remarkably
diﬃcult to identify compounds that are eﬃcacious
against pathogens within the acidic environment of
the phagolysosomes in which they thrive in host
macrophages. The presence of these pathogens
within granulomas that further restrict the local
accumulation of drugs (Kjellsson et al. 2012) has
yet to be surmounted in investigative PK studies. No
available animal models give a reliable reﬂection of
the human host environment which contributes to
the diﬃculties that have been so problematic in
identifying suitable drugs for these organisms. As we
better appreciate these issues, so the need for better,
more predictive in vitro and in vivo models for drug
development becomes ever more clear.
THE CHANGING DRUG DEVELOPMENT
LANDSCAPE, PRODUCT DEVELOPMENT
PARTNERSHIPS , RE-ENGAGING PHARMA AND
OPEN SOURCE DRUG DEVELOPMENT
By the late 1990s, a series of mergers within the
pharmaceutical industry, accompanied by business
models dependent upon identifying block-buster
drugs that could be sold at high prices for the chronic
diseases common in the aﬄuent west, were impacting
adversely on anti-pathogen drug development. Short
doses of cheap curative drugs were the norm for most
infectious diseases within the developed world. For
the cohort of diseases that aﬄict predominantly the
world’s poorest people, the required investments
reaching many millions of dollars for development,
could not be put forwardwith no prospect of a return.
It was to this back-drop that in 1998 the Global
Alliance for Tuberculosis was founded followed by
MMV in 1999. In 2003, the Drugs for Neglected
Diseases initiative emerged with a remit to seek
new agents for HAT, leishmaniasis and Chagas
disease (Don and Ioset, 2013). Other PDPs, such
as the Consortium for Parasitic Drug Development
(CPDD), received substantial backing from the Bill
and Melinda Gates Foundation to take the orally
available diamidine pro-drug, pafuramidine, forward
for HAT (Paine et al. 2010) and the Institute of One
World Health (iOWH) took paromomycin forward
for visceral leishmaniasis (Sundar et al. 2007).
Elsewhere academic-based laboratories, for example
the Drug Discovery Unit in Dundee and the Center
for Discovery and Innovation in Parasitic Diseases at
UCSF, have dedicated themselves to drug discovery
with the PDPs oﬀering natural points for handing
over optimized leads for clinical development. The
growth of the PDPs and increased level of sophisti-
cation in academic drug discovery has also seen a new
acceptance within the pharmaceutical industry that
competence is now available for them to engage in the
area. Pharmaceutical companies have made com-
pound libraries available for large screens against
HAT, leishmania, Chagas disease, malaria, tubercu-
losis and other infections, and signiﬁcant hits have
emerged. Moreover, several large pharmaceutical
companies have also re-launched their own pro-
grammes in drug discovery for tropical diseases.
GSK Tres Cantos (Spain) is one of the leaders,
making available the data from their malaria screen-
ing programme. In addition the GSKOpen lab oﬀers
opportunities for academics and small biotech
companies to work within a GSK development
environment (Jimanez-Diaz et al. 2013). Novartis
established a tropical disease research facility in
Singapore in 2004, with a current focus on malaria
(Smith et al. 2013), dengue and HAT. The adoption
by industry of pre-competitive models for drug
discovery emulates many of these changes and
oﬀers opportunities to extend public private inter-
actions into new disease areas. Another interesting
growth area has been the emergence of open-source
drug discovery where ideas on chemical synthesis can
be exchanged on line to accelerate the resolution of
problems in chemical synthesis as was successfully
demonstrated in separating enantiomers of the anti-
schistosomal drug praziquantel (Robertson et al.
2013).
A largely overlooked area of anti-pathogen chemo-
therapy has been the development of novel drugs
against helminth infections. Given that billions of
people the world over are aﬄicted with one or more
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parasitic helminth species it has been extraordinary
that so little eﬀort has gone into developing novel
agents against the human helminthiases (Keiser and
Utzinger, 2010). The fact that several orally available,
relatively safe and eﬃcacious drugs, developed
initially for the veterinary market, exist has been a
disincentive towards development, as has the fact that
many of the helminthiases are not in themselves life
threatening. However, with the realization that these
neglected tropical diseases do have a huge impact
on human populations, interest in this area has been
reinvigorated (Hotez et al. 2008). With it comes a
new series of challenges around targeting organisms
that pass through multiple life-cycle stages in their
host (targeting adult vs larval worm stages requires
diﬀerent compounds in many cases) (Taylor et al.
2013). The presence of relatively large organisms,
with multiple organ systems and a protective cuticle
is presenting a new wave of challenges for those
interested in developing drugs for these diseases.
POTENTIAL RISKS TO A DECADE OF PROGRESS
For the ﬁrst time in history a robust pipeline of
rationally selected compounds for development
against malaria has been developed (Burrows et al.
2013). Elsewhere, less robust pipelines, but pipelines
nevertheless, have emerged for treatment of human
African trypanosomiasis, leishmaniasis, Chagas dis-
ease, tuberculosis and other neglected diseases. The
paradigms that have emerged to create these pipelines
are now being applied to other parasitic and bacterial
diseases. Comparing the status of the diﬀerent
pipelines indicates that the tropism and behaviour
of pathogens within the host is a main determinant
with the ease by which we may target drugs to
them. From an optimist’s perspective our increased
appreciation of the barriers that selectively hinder
development of drugs for diﬀerent pathogens en-
courages the belief that the dissection of these
problems and adoption of pharmacological ap-
proaches to breach the blood-brain barrier, granulo-
ma barriers or the harsh acidic environment of the
macrophage mean a way ahead is possible.
The focus must now be to sustain the successes
of the past decade to ensure the tools are available
for more eﬀective treatment of patients, control of
diseases in populations and eventual elimination or
eradication. For some diseases, for example malaria,
the demands are high with need for diﬀerent types
of drugs, exhibiting a variation of mechanisms of
action and pharmacokinetic properties, to be used
for diﬀerent purposes in treatment and control
(Burrows et al. 2013). For malaria, this has led to
new deﬁnitions of target clinical proﬁles and illus-
trates the need for several new drugs, and safe eﬀec-
tive multi-stage combinations of these drugs.
Combination therapy has long been a complexity
for those developing drugs for tuberculosis where
issues of drug–drug interaction and pharmaceutical
formulation have to be addressed in parallel with
clinical development. Other demands face neglected
diseases. In the case of HAT, the incidence of the
disease has declined substantially over the past
decade, with fewer than 7000 new cases reported in
2011 (Simarro et al. 2012). This has led many
funding agencies to question whether there is a
need to continue investing in new tools when existing
tools, such as the nifurtimox–eﬂornithine combi-
nation (NECT), can be demonstrably eﬀective when
used correctly, despite the facts that these existing
tools are generally highly unsatisfactory as drugs.
Resistance to eﬂornithine is very readily selected
(Vincent et al. 2010) and reports of treatment failure
to eﬂornithine monotherapy are already emerging
from parts of Africa. The pipeline is not yet
suﬃciently robust to cover loss of drugs to resistance.
For leishmaniasis too, the existing drugs suﬀer many
limitations and the realization that for every clinically
recognized case of leishmaniasis there are probably
10 undiagnosed, asymptomatic infections oﬀering a
potential reservoir that will seriously hinder any
elimination programme. Liposomal amphotericin B
and new combinations have been hailed as a tool for
elimination and oﬀer the potential advantage of
shorter course treatments against visceral leishma-
niasis where cost, delivery to populations, and
stability plus diﬀerences in eﬃcacy between India
and Sudan remain key issues (Croft and Olliaro,
2011).
There must be a degree of pragmatism among the
communities involved in developing drugs for these
pathogens. The paradigm of bringing compounds
into PDPs, where robust pharmacological data
combines with potency studies to drive development,
clearly works. Further expansion of the role of
pharmaceutical companies, integration of the activi-
ties of existing PDPs, support for innovation in the
academic and biotech sectors, enhanced sharing of
information and an insistence on global standards
for the development of new compounds for these
diseases is theway ahead. The implementation of new
drugs in programmes for the treatment, control and
elimination/eradication of these diseases also requires
more forethought, planning and commitment of
funds and support for health systems.
ACKNOWLEDGEMENTS
The meeting organisers are grateful to Cambridge
University Press, Cipla, Novartis, Pharmidex and
SCYNEXIS for their generous sponsorship of themeeting.
REFERENCES
Anthony, M. P., Burrows, J. N., Duparc, S., Moehrle, J. J. and
Wells, T.N. (2012). The global pipeline of new medicines for the control
and elimination of malaria. Malaria Journal 11, 316.
Booker, M. L., Bastos, C.M., Kramer, M. L., Barker, R. H., Jr.,
Skerlj, R., Sidhu, A. B., Deng, X., Celatka, C., Cortese, J. F.,
5Preface: Anti-infective drug design
Guerrero Bravo, J. E., Crespo Llado, K. N., Serrano, A. E., Angulo-
Barturen, I., Jiménez-Díaz, M. B., Viera, S., Garuti, H., Wittlin, S.,
Papastogiannidis, P., Lin, J.W., Janse, C. J., Khan, S.M.,
Duraisingh, M., Coleman, B., Goldsmith, E. J., Phillips, M. A.,
Munoz, B., Wirth, D. F., Klinger, J. D., Wiegand, R. and Sybertz, E.
(2010). Novel inhibitors of Plasmodium falciparum dihydroorotate dehy-
drogenase with anti-malarial activity in the mouse model. Journal of
Biological Chemistry 285, 33054–33064.
Burrows, J. N., Burlot, E., Campo, B., Cherbuin, S., Jeanneret, S.,
Leroy, D., Spangenberg, T., Waterson, D., Wells, N. C. and Willis, P.
(2013). Antimalarial drug discovery – the path towards eradication.
Parasitology 141, 128–139.
Centers for Disease Control and Prevention. (2012). Progress toward
global eradication of dracunculiasis–January 2011-June 2012.Morbidity and
Mortality Weekly Report 61, 854–857.
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C.,
Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., III,
Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T.,
Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S.,
Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Krogh, A.,
McLean, J., Moule, S., Murphy, L., Oliver, K., Osborne, J.,
Quail, M. A., Rajandream, M. A., Rogers, J., Rutter, S., Seeger, K.,
Skelton, J., Squares, R., Squares, S., Sulston, J. E., Taylor, K.,
Whitehead, S. and Barrell, B. G. (1998). Deciphering the biology of
Mycobacterium tuberculosis from the complete genome sequence. Nature
393, 537–544.
Creek, D. J. and Barrett, M. P. (2013). Determination of anti-
protozoal drug mechanisms by metabolomics approaches. Parasitology
141, 83–92.
Croft, S. L. (2005). Public-private partnership: from there to here.
Transaction of the Royal Society of Tropical Medicine and Hygiene 99
(Suppl. 1), S9–S14.
Croft, S. L. and Olliaro, P. (2011). Leishmaniasis chemotherapy –
challenges and opportunities.Clinical Microbiology Infection 17, 1478–1483.
Cunningham, F., McPhillie, M. J., Johnson, A. P. and
Fishwick, C.W. G. (2013). An in silico structure-based approach to anti-
infective drug discovery. Parasitology 141, 17–27.
Don, R. and Ioset, J. R. (2013). Screening strategies to identify new
chemical diversity for drug development to treat kinetoplastid infections.
Parasitology 141, 140–146.
El-Sayed, N.M., Myler, P. J., Blandin, G., Berriman, M., Crabtree, J.,
Aggarwal, G., Caler, E., Renauld, H., Worthey, E. A., Hertz-
Fowler, C., Ghedin, E., Peacock, C., Bartholomeu, D. C., Haas, B. J.,
Tran, A. N., Wortman, J. R., Alsmark, U. C., Angiuoli, S.,
Anupama, A., Badger, J., Bringaud, F., Cadag, E., Carlton, J.M.,
Cerqueira, G. C., Creasy, T., Delcher, A. L., Djikeng, A.,
Embley, T.M., Hauser, C., Ivens, A. C., Kummerfeld, S. K.,
Pereira-Leal, J. B., Nilsson, D., Peterson, J., Salzberg, S. L.,
Shallom, J., Silva, J. C., Sundaram, J., Westenberger, S., White, O.,
Melville, S. E., Donelson, J. E., Andersson, B., Stuart, K. D. and
Hall, N. (2005). Comparative genomics of trypanosomatid parasitic
protozoa. Science 309, 404–409.
Fairlamb, A. H., Blackburn, P., Ulrich, P., Chait, B. T. and
Cerami, A. (1985). Trypanothione: a novel bis(glutathionyl)spermidine
cofactor for glutathione reductase in trypanosomatids. Science 227,
1485–1487.
Frearson, J. A., Brand, S., McElroy, S. P., Cleghorn, L. A.,
Smid, O., Stojanovski, L., Price, H. P., Guther, M. L., Torrie, L. S.,
Robinson, D. A., Hallyburton, I., Mpamhanga, C. P., Brannigan, J. A.,
Wilkinson, A. J., Hodgkinson, M., Hui, R., Qiu, W., Raimi, O. G., van
Aalten, D.M., Brenk, R., Gilbert, I. H., Read, K. D., Fairlamb, A. H.,
Ferguson, M. A., Smith, D. F. and Wyatt, P. G. (2010). N-myristoyl-
transferase inhibitors as new leads to treat sleeping sickness. Nature 464,
728–732.
Gamo, F. J., Sanz, L.M., Vidal, J., de Cozar, C., Alvarez, E.,
Lavandera, J. L., Vanderwall, D. E., Green, D. V., Kumar, V.,
Hasan, S., Brown, J. R., Peishoﬀ, C. E., Cardon, L. R. and Garcia-
Bustos, J. F. (2010). Thousands of chemical starting points for antimalarial
lead identiﬁcation. Nature 465, 305–310.
Garcia-Alvarez, L., Dawson, S., Cookson, B. and Hawkey, P. (2012).
Working across the veterinary and human health sectors. Journal of
Antimicrobial Chemotherapy 67(Suppl. 1):i37–i49.
Gilbert, I. H. (2013). Target-based drug discovery for human African
trypanosomiasis: selection of molecular target and chemical matter.
Parasitology 141, 28–36.
Greenwood, D. (1995). Conﬂicts of interest: the genesis of synthetic
antimalarial agents in peace and war. Journal of Antimicrobial Chemotherapy
36, 857–872.
Greenwood, D. (2008). Antimicrobial drugs. Chronicle of a Twentieth
Century Medical Triumph, pp. 368. Oxford University Press, Oxford, UK.
Guttman, P. and Ehrlich, P. (1891). Ueber die Wirkung des
Methylenblau bei Malaria. Berliner Klinische 28, 953–956.
Haydel, S. E. (2010). Extensively drug-resistant tuberculosis: a sign of the
times and an impetus for antimicrobial discovery. Pharmaceuticals (Basel)
3, 2268–2290.
Horn, D. (2013). High-throughput decoding of drug targets and
drug resistance mechanisms in African trypanosomes. Parasitology 141,
77–82.
Hotez, P. J., Brindley, P. J., Bethony, J.M., King, C. H., Pearce, E. J.
and Jacobson, J. (2008). Helminth infections: the great neglected tropical
diseases. Journal of Clinical Investigation 118, 1311–1321.
Iyengar, R., Zhao, S., Chung, S.W., Mager, D. E. and Gallol, J. M.
(2012). Merging Systems Biology with Pharmacodynamics. Science
Translational Medicine 4, ps7.
Jacobs, R. T., Nare, B.,Wring, S. A., Orr,M. D., Chen, D., Sligar, J. M.,
Jenks, M. X., Noe, R. A., Bowling, T. S., Mercer, L. T., Rewerts, C.,
Gaukel, E., Owens, J., Parham, R., Randolph, R., Beaudet, B.,
Bacchi, C. J., Yarlett, N., Plattner, J. J., Freund, Y., Ding, C.,
Akama, T., Zhang, Y. K., Brun, R., Kaiser, M., Scandale, I. and
Don, R. (2011). SCYX-7158, an orally-active benzoxaborole for the
treatment of stage 2 human African trypanosomiasis. PLoS Neglected
Tropical Diseases 5, e1151.
Jimanez-Diaz, M. B., Viera, S., Fernandez-Alvaro, E. and Angulo-
Barturen, I. (2013). Animal models of eﬃcacy to accelerate drug discovery
in malaria. Parasitology 141, 93–103.
Keiser, J. and Utzinger, J. (2010). The drugs we have and the drugs
we need against major helminth infections. Advances in Parasitology 73,
197–230.
Kjellsson, M. C., Via, L. E., Goh, A., Weiner, D., Low, K.M.,
Kern, S., Pillai, G., Barry, C. E., III and Dartois, V. (2012).
Pharmacokinetic evaluation of the penetration of antituberculosis agents
in rabbit pulmonary lesions. Antimicrobial Agents and Chemotherapy 56,
446–457.
Knight, Z. A., Lin, H. and Shokat, K.M. (2010). Targeting the
cancer kinome through polypharmacology. Nature Reviews Cancer 10,
130–137.
Minor, P. D. (2012). Polio vaccines and the eradication of poliomyelitis.
Lancet 380, 454–455.
Nathan, C. (2012). Fresh approaches to anti-infective therapies. Science
Translational Medicine 4, 140sr2.
Norcliﬀe, J. L., Alvarez-Ruiz, J. J., Martin-Plaza, P. G. and
Denny, P.W. (2013). The utility of yeast as a tool for cell-based, target-
directed high-throughput screening. Parasitology 141, 8–16.
Ockenhouse, C. F., Magill, A., Smith, D. and Milhous, W. (2005).
History of U.S. military contributions to the study of malaria. Military
Medicine 170(Suppl.), 12–16.
Paine, M. F., Wang, M. Z., Generaux, C. N., Boykin, D.W.,
Wilson, W. D., De Koning, H. P., Olson, C. A., Pohlig, G., Burri, C.,
Brun, R.,Murilla, G. A., Thuita, J. K., Barrett,M. P. andTidwell, R. R.
(2010). Diamidines for human African trypanosomiasis. Current Opinion in
Investigative Drugs 11, 876–883.
Payne, D. J., Gwynn, M.N., Holmes, D. J. and Pompliano, D. L.
(2007). Drugs for bad bugs: confronting the challenges of antibacterial
discovery. Nature Reviews Drug Discovery 6, 29–40.
Piddock, L. J. (2012). The crisis of no new antibiotics–what is the way
forward? Lancet Infectious Diseases 12, 249–253.
Robertson, M., Ylioja, P., Woelﬂe, M., Robins, M., Williamson, A.,
Badiola, K., Olliaro, P., Wells, T. N. C. and Todd, M.H.
(2013). Open source drug discovery – A limited tutorial. Parasitology
141, 148–157.
Simarro, P. P., Cecchi, G., Franco, J. R., Paone, M., Diarra, A.,
Ruiz-Postigo, J. A., Fèvre, E.M., Mattioli, R. C. and Jannin, J. G.
(2012). Estimating and mapping the population at risk of sleeping sickness.
PLoS Neglected Tropical Diseases 6, e1859.
Smith, P.W., Diagana, T. T. and Yeung, B. K. S. (2013). Progressing the
global antimalarial portfolio: ﬁnding drugs which target multiple
Plasmodium life stages. Parasitology 141, 66–76.
Stocks, P. A., Barton, V., Antoine, T., Biagnini, G. A., Ward, S. A. and
O’Neill, P.M. (2013). Novel inhibitors of the Plasmodium falciparum
electron transport chain. Parasitology 141, 50–65.
Sundar, S., Jha, T.K., Thakur, C. P., Sinha, P. K. and
Bhattacharya, S. K. (2007). Injectable paromomycin for Visceral leishma-
niasis in India. New England Journal of Medicine 356, 2571–2581.
Tate, E.W., Bell, A. S., Rackham, M. D. and Megan, H. (2013).
N-Myristoyltransferase as a potential drug target in malaria and leishma-
niasis. Parasitology 141, 37–49.
6Michael P. Barrett and Simon L. Croft
Taylor, M. J., Hoerauf, A., Townson, S., Slatko, B. and Ward, S.
(2013). Anti-Wolbachia (A·WOL) drug discovery and development: safe
macroﬁlaricides for onchocerciasis and lymphatic ﬁlariasis. Parasitology
141, 119–127.
Vincent, I.M., Creek, D., Watson, D. G., Kamleh, M. A., Woods, D. J.,
Wong, P. E., Burchmore, R. J. and Barrett, M. P. (2010). A molecular
mechanism for eﬂornithine resistance in African trypanosomes. PLoS
Pathogens 6, e1001204.
Wang, H., Dwyer-Lindgren, L., Lofgren, K. T., Rajaratnam, J. K.,
Marcus, J. R., Levin-Rector, A., Levitz, C. E., Lopez, A. D. and
Murray, C. J. (2012). Age-speciﬁc and sex-speciﬁc mortality in 187
countries, 1970–2010: a systematic analysis for the Global Burden of
Disease Study 2010. Lancet 380, 2071–2094.
Watanabe, Y., Ibrahim, M. S., Suzuki, Y. and Ikuta, K. (2012). The
changing nature of avian inﬂuenza A virus (H5N1). Trends in Microbiology
20, 11–20.
Weinstein, R. A. (2004). Planning for epidemics–the lessons of SARS.
New England Journal of Medicine 350, 2332–2334.
White, N. J. (2012). Counter perspective: artemisinin resistance:
facts, fears, and fables. American Journal of Tropical Medicine and Hygiene
87, 785.
Wirth, D. F. (2002). Biological revelations. Nature 419, 495–496.
Witty, A. (2011). New strategies for innovation in global health: a
pharmaceutical industry perspective. Health Aﬀairs (Millwood) 30,
118–126.
Wring, S., Gaukel, E., Nare, B., Jacobs, R., Beaudet, B., Bowling, T.,
Mercer, L., Bacchi, C., Yarlett, N., Randolph, R., Parham, R.,
Rewarts, C., Platerner, J. and Don, R. (2013). Pharmacokinetics
and pharmacodynamics utilizing unbound target tissue exposure as part
of a disposition-based rationale for lead optimization of benzoxaboroles
in the treatment of stage 2 Human African Trypanosomiasis. Parasitology
141, 104–118.
7Preface: Anti-infective drug design
